Glycoside Hydrolase Inhibitors

Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES.

Also Known As:

Intestinal alpha-Amylase Inhibitors; Pancreatic alpha-Amylase Inhibitors; alpha-Amylase Inhibitors, Pancreatic; Hydrolase Inhibitors, Glycoside; Inhibitor, alpha-Glucosidase; Inhibitors, Glycoside Hydrolase; Inhibitors, Intestinal alpha-Amylase; Inhibitors, Pancreatic alpha-Amylase; Inhibitors, alpha-Glucosidase; Intestinal alpha Amylase Inhibitors; Pancreatic alpha Amylase Inhibitors; alpha Amylase Inhibitors, Pancreatic; alpha Glucosidase Inhibitor; alpha Glucosidase Inhibitors; alpha-Amylase Inhibitors, Intestinal; alpha-Glucosidase Inhibitor; alpha-Glucosidase Inhibitors

Networked: 373 relevant articles (37 outcomes, 69 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Glycoside Hydrolase Inhibitors: 373
  - Physiological Effects of Drugs: 1
    - Hypoglycemic Agents: 14973
      - Glycoside Hydrolase Inhibitors: 373

Experts

1.	Kawamori, Ryuzo: 6 articles (11/2013 - 06/2004)
2.	Ji, Linong: 5 articles (01/2019 - 01/2013)
3.	Cai, Xiaoling: 4 articles (03/2018 - 01/2013)
4.	Han, Xueyao: 4 articles (03/2018 - 01/2013)
5.	Watada, Hirotaka: 4 articles (05/2016 - 07/2007)
6.	Kalinowski, Jörn: 4 articles (01/2015 - 03/2012)
7.	Pühler, Alfred: 4 articles (01/2015 - 03/2012)
8.	Rückert, Christian: 4 articles (01/2015 - 03/2012)
9.	Hanefeld, Markolf: 4 articles (07/2012 - 07/2003)
10.	Rosak, Christoph: 4 articles (01/2012 - 01/2002)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 02/01/2006 - "Are alpha-glucosidase inhibitors effective for control of type 2 diabetes?" 06/01/1994 - "To compare the different therapeutic principles of alpha-glucosidase inhibitors and sulphonylureas as first-line treatment in non-insulin-dependent diabetes mellitus (NIDDM) patients with dietary failure. " 05/01/1998 - "alpha-glucosidase inhibitors are a useful and relatively safe therapeutic option in the elderly patient with type 2 diabetes." 10/01/1997 - "The purpose of the study was to examine the relationship between gastric emptying and the efficacy of an alpha-glucosidase inhibitor in NIDDM patients. " 01/01/2013 - "Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian."
2.	Hyperglycemia 07/01/2002 - "These results suggest that the extract from ezoishige has potent alpha-glucosidase inhibitors and would be effective for suppressing postprandial hyperglycemia." 05/01/2010 - "Recent clinical studies have demonstrated that alpha-glucosidase inhibitors that improve postprandial hyperglycemia, can prevent the development of diabetes from IGT. " 04/07/2011 - "Aims/Introduction: Although the improvement of postprandial hyperglycemia by an alpha-glucosidase inhibitor (α-GI) has been associated with a risk reduction of cardiovascular events, the relationship between postprandial hyperglycemia and arterial stiffness has not been well understood. " 06/03/2005 - "Punica granatum flower extract, a potent alpha-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats." 06/19/2013 - "Alpha-glucosidase inhibitors (α-GIs) improve postprandial hyperglycemia (PPHG) and may have favorable effects on associated cardiovascular disease. "
3.	Glucose Intolerance 01/01/2008 - "In patients with impaired glucose tolerance, the concomitant use of an alpha-glucosidase inhibitor with LES might be a useful measure for nutritional management." 10/01/1998 - "The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. " 09/01/2009 - "[Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]." 08/01/1998 - "Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance." 10/18/2006 - "To assess the effects of alpha-glucosidase inhibitors in patients with impaired glucose tolerance (IGT) or impaired fasting blood glucose (IFBG), or both. "
4.	Heart Failure 10/01/2006 - "Alpha-glucosidase inhibitors: new therapeutic agents for chronic heart failure." 01/01/2019 - "Correction: The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial." 01/01/2019 - "The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial." 04/01/2006 - "Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice." 10/01/2005 - "No association with hospitalization for heart failure was found for patients exposed to a sulfonylurea, metformin, or alpha-glucosidase inhibitor. "
5.	Cardiovascular Diseases (Cardiovascular Disease) 05/01/2010 - "Additionally, alpha-glucosidase inhibitors have been shown to inhibit the progression of cardiovascular disease. " 06/19/2013 - "Alpha-glucosidase inhibitors (α-GIs) improve postprandial hyperglycemia (PPHG) and may have favorable effects on associated cardiovascular disease. " 08/01/2004 - "Recently, the STOP-NIDDM trial has been shown that patients with impaired glucose tolerance treated with the alpha-glucosidase inhibitor acarbose had a significant reduction in the risk of cardiovascular disease. " 07/01/2010 - "Improvement in post-prandial hyperglycemia on alpha-glucosidase inhibitors (alpha-GIs) is associated with a risk reduction of cardiovascular diseases, but the post-prandial effects of alpha-GIs on endothelial function and incretin secretion in type 2 diabetic patients with coronary artery disease (CAD) remain unclear. " 10/18/2006 - "Alpha-glucosidase inhibitors (AGIs) reduce blood glucose levels and may thus prevent type 2 diabetes and cardiovascular disease in patients with impaired glucose tolerance. "

Related Drugs and Biologics

1.	Acarbose
2.	voglibose (Basen)
3.	Insulin (Novolin)
4.	Metformin (Glucophage)
5.	Glucose (Dextrose)
6.	miglitol (Glyset)
7.	Sodium-Glucose Transport Proteins
8.	Lipids
9.	1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitol
10.	Blood Glucose (Blood Sugar)

Related Therapies and Procedures

1.	Glycemic Control
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Carbohydrate-Restricted Diet (Low Carbohydrate Diet)
5.	Gastrectomy